Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Biogen Idec | Contract Pharma
Breaking News, Promotions & Moves

Biogen Idec

Michael E. Lytton has been appointed executive vice president, business and corporate development, Biogen Idec. Mr. Lytton will be responsible for leading the company's business development activities.

Michael E. Lytton has been appointed executive vice president, business and corporate development, Biogen Idec. Mr. Lytton will be responsible for leading the company’s business development activities.
 
“Michael brings more than 25 years of business development, investment and legal experience in the biotechnology industry,” said Biogen Idec chief operating officer Hans Peter Hasler. “His M&A background, as well as his experience in identifying and translating promising science into successful companies, makes him uniquely qualified to build on our track record of highly disciplined and productive business development.”

For the past eight years, Mr. Lytton served as a general partner at Oxford Bioscience Partners, a venture capital firm that provides assistance to emerging life sciences companies. During his tenure, Mr. Lytton led investments in a range of therapeutic areas, including central nervous system disorders, inflammatory diseases and oncology. He worked with management and boards of portfolio companies to drive growth through restructurings, M&A and exits through sales to larger companies. From 1993 to 2000, he was partner, chairman of the Technology Group, and a member of the Executive Committee of Palmer & Dodge LLP, a Boston-based law firm.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters